Navigation Links
US Patent Granted for a New Family of Heat Shock Protein 90 (Hsp90) Inhibitors for the Treatment of Cancer and Neurodegenerative Indications
Date:5/19/2011

NEW YORK, May 19, 2011 /PRNewswire/ -- NexGenix Pharmaceuticals Inc., a privately-held company developing treatments for cancer, neurodegenerative diseases, and orphan neurogenetic disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent for a platform of Hsp90 inhibitors based on derivatives of the  naturally occurring pochonin family, Pochonia chlamydospora.  The platform of fully synthetic small molecules covered by this composition of matter patent was developed in the laboratory of Dr. Nicolas Winssinger at the University of Strasbourg (UNISTRA) and is exclusively licensed to NexGenix.

The patent, entitled "Macrocyclic Compounds Useful as Inhibitors of Kinases and Hsp90", provides an exclusivity period until August 2027.  The patent specifically covers the proprietary scaffold and its composition along with a large library of compounds, including NexGenix's lead Hsp90 inhibitors aimed at cancer and neurodegenerative indications.  The pochonin scaffold represents an advancement in Hsp90 inhibition beyond several molecules developed over the last decade based on radicicol and geldanamycin derivative (17-AAG) which have been shown to exhibit highly potent anti-tumor activity in numerous pre-clinical and clinical studies.

Professor Nicolas Winssinger of UNISTRA stated, "Through a research collaboration agreement with NexGenix in 2007, we have developed a library of hundreds of molecules based on the scaffold that is covered by the patent allowed by USPTO. These molecules have been developed through an iterative process based on extensive in vitro and in vivo studies conducted by NexGenix in the selection of a lead candidate. I am looking forward to continuing these collaborative development activities."

X-ray crystallography studies have demonstrated deeper binding of NexGenix's molecules to the Hsp90 ATP binding pocket compared to other small-
'/>"/>

SOURCE NexGenix Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark Patents Issued for ViewRay Technology
2. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
3. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
4. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
5. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
6. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
7. Rosetta Genomics Announces Issuance of Additional U.S. Patent
8. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
9. IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery
10. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
11. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014  Indianapolis ... and Toronto -based 3D visualization ... the Congress of Neurological Surgeons Annual Meeting that ... technologies for brain surgery. The collaboration is the ... powerful combination to improve patient outcomes. NICO,s BrainPath® ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... and INDIANAPOLIS , March 15 ... evaluated response rates in patients with a common genetic ... TRITON-TIMI 38 study were treated with dual antiplatelet therapy ... plus aspirin and managed with percutaneous coronary intervention (PCI) ...
... March 15 At this year,s annual meeting ... 14-16 in Atlanta , Royal Philips Electronics ... simplifying cardiology patient care by highlighting a range of ... tools, intuitive information management systems, new temperature modulation therapies, ...
Cached Medicine Technology:New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 2New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 3New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 4New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 5New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 6New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 7New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 8New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 9New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 10New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 11Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 2Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 3Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 4Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 5Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 6Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 7Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 8Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 9
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment ... Institutes for Research (AIR) finds that three out of four ... but 42 percent say they are not likely or only ... for coverage. , The AIR survey found wide gaps in ... calculate correctly how much they owe for a routine doctor’s ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... SNM,s 57th Annual Meeting WHAT: Registration to the ... openand freefor members of the media WHEN: June ... Lake City, Utah MORE INFO: Registration is free ... letter of assignment. The online meeting planner is available ...
... more, not less, use, study finds , FRIDAY, March ... can backfire, suggests a U.S. study. , Researchers interviewed ... ads that used guilt or shame to warn against ... instinctive coping mechanism that enables people who see them ...
... ... ... ... ...
... TEMPE, Ariz. Leading futurists and technologists have worked ... "Grand Challenges for Engineering in the 21st Century," focusing ... improve the quality of life in a growing and ... to action toward achieving these goals, the Ira A. ...
... can lead to unneeded treatments with unwanted side ... -- New American Cancer Society guidelines on prostate ... faced with a cascade of decisions, with a ... shoulders. , The guidelines, issued Wednesday, de-emphasize routine ...
... ... --HealthCare Partners of Nevada, a Las Vegas-based healthcare organization, announced the acquisition of Rainbow Medical ... Nevada. Rainbow Medical Center is now part of the Fremont Medical Centers Division of ... ...
Cached Medicine News:Health News:Anti-Drinking Ads That Engender Guilt May Not Work 2Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 2Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 3Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 4Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 5Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 6Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 7Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 8Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 9Health News:Summit seeks to spark call to action on facing world's biggest challenges 2Health News:New Prostate Cancer Guidelines Aim to Empower the Patient 2Health News:New Prostate Cancer Guidelines Aim to Empower the Patient 3Health News:New Prostate Cancer Guidelines Aim to Empower the Patient 4Health News:HealthCare Partners of Nevada and Rainbow Medical Center Join Forces 2
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
Keep your laboratory efficient. And meet your volume needs. When you set the pace with the Clinitek 500 Urine Chemistry Analyzer. Its ready when you are. No warm-up. No calibration. No bells. Just pr...
... pressure sensor catheters incorporate a ... injection/guide wire, or high-speed injection/guide ... high-speed injection has two laterally ... an open-end pigtail extension for ...
... catheters provide a simple, efficient and ... in the heart or cardiovascular system. ... ideal for high fidelity pressure measurement. ... 2 to 7 French and in ...
Medicine Products: